UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstracts for References 56,62-64

of '化疗引起的脱发'

56
TI
Scalp hypothermia in the prevention of chemotherapy-induced alopecia.
AU
Vendelbo Johansen L
SO
Acta Radiol Oncol. 1985;24(2):113.
 
Alopecia is a common side effect of cancer chemotherapy, especially in combination with regimens with doxorubicin (Adriamycin). The effect of scalp hypothermia in connection with chemotherapy was evaluated as hair protection in 61 women with disseminated breast carcinoma, where earlier treatment routines had caused wig-requiring alopecia in nearly all patients. The cooling was performed with a gel-helmet (Hypotherm Gel-Kap). Of the 61 patients, 47 (77%) had no or slight, not wig-demanding hair loss, and 14 (23%) had severe (wig-demanding) hair loss. Seven patients had liver dysfunction; in 5 of these severe hair loss was observed; 2 had slight hair loss. Eighty-three per cent of the patients with normal liver function had no hair loss. Treatment tolerance was found to be good, and side effects were minimal. The method is found to be simple, effective and inexpensive, though still not technically optimal.
AD
PMID
62
TI
The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia.
AU
Parker R
SO
Oncol Nurs Forum. 1987;14(6):49.
 
AD
PMID
63
TI
Clinical observations of scalp cooling in patients receiving multidrug chemotherapy
AU
Knobf M, Kalm D, Mealia M
SO
Oncol Nurs Forum. 1989;16(suppl):200.
 
AD
64
TI
Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine.
AU
Middleton J, Franks D, Buchanan RB, Hall V, Smallwood J, Williams CJ
SO
Cancer Treat Rep. 1985;69(4):373.
 
Scalp hypothermia can prevent alopecia caused by low doses of doxorubicin alone or in simple combinations. The technique was used in 60 patients with breast cancer (24 receiving adjuvant therapy; 36 with advanced recurrent disease) receiving chemotherapy with iv doxorubicin (40 mg/m2) and vincristine (1.4 mg/m2) on Day 1 together with oral cyclophosphamide (200 mg/m2) on Days 2-5. The patients' desire to continue scalp hypothermia, reflecting their perception of benefit, and an objective assessment of hair retention were the study end points. The mean number of cycles of chemotherapy given (6.1 in patients receiving adjuvant therapy; 3.8 in those with advanced disease) exceeded the number of cycles with hypothermia (2.1 in patients receiving adjuvant therapy; 1.6 in those with advanced disease); no patients retained enough hair to encourage them to continue scalp hypothermia throughout chemotherapy. All patients were rated as having poor hair retention. Scalp hypothermia is ineffective when used with combinations of drugs, each causing alopecia, or with high doses of doxorubicin.
AD
PMID